Table 1. PARP inhibitors in clinical development.
| PARP inhibitor | Route of administration | Clinical development | Histology | Company |
| AG014699 | Intravenous | Phase II | Melanoma, breast cancer | Pfizer |
| Veliparib (ABT 888) | Oral | Phase II | Melanoma, breast cancer, glioblastoma, ovarian cancer | Abbott |
| Olaparib (AZ 2281, KU59436) | Oral | Phase II | Breast cancer, ovarian cancer, melanoma | AstraZeneca |
| Iniparib (BSI 201)/BSI 401 | Intravenous/oral | Phase III | Breast cancer, non–small cell lung cancer | Sanofi-Aventis/BiPar Sciences |
| MK4827 | Oral | Phase I | Ovarian cancer | Merck |
| CEP 9722 | Oral | Phase I | Cephalon | |
| BMN-673 | Oral | Phase I | Biomarin | |
| E7016 | Oral | Phase I | Eisai |